Travere Therapeutics, Inc.

TVTX Net selling

CIK 0001438533 #1223 in the set updated 17 Sep 2026

Bought (120 mo)

$89.25K

out of their own pocket, the only kind of buying there is

Sold (120 mo)

$64.26M

$14.01M on a plan · $34.80M straight out of an exercise

Sold at will

$15.45M

267 of 395 sales

Net

−$64.17M

−$15.36M against sales at will

By person

21 insiders · 397 transactions

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Dube Eric M

CHIEF EXECUTIVE OFFICER

—

$21.24M (45) scheduled

−$21.24M

432,886

0.4592%

$29.47M

—

ASELAGE STEVE

Director

$89.25K (1)

$7.30M (40) scheduled

−$7.21M

166,419

0.1766%

$11.33M

−50.4%

REED ELIZABETH E

Chief Legal Officer and GC

—

$6.93M (66) scheduled

−$6.93M

105,211

0.1116%

$7.16M

+6,799%

Calvin Sandra

SVP, CHIEF ACCOUNTING OFFICER

—

$5.96M (27) scheduled

−$5.96M

42,353

0.0449%

$2.88M

+40.5%

ROTE WILLIAM E.

Chief Research Officer

—

$5.22M (53) scheduled

−$5.22M

115,474

0.1225%

$7.86M

+1,018%

Baynes Roy D.

Director

—

$3.09M (8) scheduled

−$3.09M

41,500

0.0440%

$2.83M

+937.5%

Inrig Jula

CHIEF MEDICAL OFFICER

—

$2.72M (24) scheduled

−$2.72M

112,770

0.1196%

$7.68M

—

Meckler Jeffrey A

Director

—

$2.27M (6) scheduled

−$2.27M

91,500

0.0971%

$6.23M

+69.4%

Heerma Peter

CHIEF COMMERCIAL OFFICER

—

$2.04M (28)

−$2.04M

140,684

0.1492%

$9.58M

+1,210%

Clague Laura

Chief Financial Officer

—

$1.93M (35)

−$1.93M

35,655

0.0378%

$2.43M

—

Cline Christopher R.

CHIEF FINANCIAL OFFICER

—

$1.82M (28) scheduled

−$1.82M

118,016

0.1252%

$8.04M

+310.9%

LYONS GARY A

Director

—

$1.55M (8) scheduled

−$1.55M

61,500

0.0652%

$4.19M

+156.3%

Coughlin Timothy

Director

—

$1.27M (3) scheduled

−$1.27M

56,250

0.0597%

$3.83M

+155.7%

McFarlane Neil F.

Chief Operating Officer

—

$552.56K (7)

−$552.56K

26,988

0.0286%

$1.84M

+56.1%

Rosenberg Noah L.

Chief Medical Officer

—

$366.78K (17)

−$366.78K

47,614

0.0505%

$3.24M

+2,185%

Squarer Ron

Director

—

—

—

39,375

0.0418%

$2.68M

—

Orwin John A

Director

—

—

—

39,375

0.0418%

$2.68M

—

Poole Sandra

Director

—

—

—

34,000

0.0361%

$2.31M

—

Bruhn Suzanne Louise

Director

—

—

—

32,750

0.0347%

$2.23M

—

Williams Brinkley Ruth

Director

—

—

—

29,750

0.0316%

$2.03M

—

KOZARICH JOHN W

Director

—

—

—

29,000

0.0308%

$1.97M

+31.8%

Individual transactions

0

Nothing of that kind in this period.

What was left out

Form 4 filings counted 416

Amendments (4/A) skipped 1

Filings about a different issuer 0

Unreadable filings 0

Joint filings 0

Sales on a Rule 10b5-1 plan 67

Sales straight out of an exercise 61

Sales at will 267

Transactions with no price 0

Shares from compensation/vesting 3,710,979

Sales filed before the plan box existed 219

History held since 2 Sep 2016